Management of Albuminuria in Hypertensive Diabetics

A Multicentre Study to Evaluate the Management of Microalbuminuria in Hypertensive Patients With Type 2 Diabetes: Improving Clinical Practice

Status

UNKNOWN

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT01907958

Acronym

CLINPRADIA

Enrollment

280

Registered

2013-07-25

Start date

2013-04-30

Completion date

2014-06-30

Last updated

2013-07-25

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Hypertension, Microalbuminuria, Type 2 Diabetes

Keywords

Microalbuminuria, Hypertensive, Diabetics, urine albumin

Brief summary

Multicenter stepped wedge cluster randomized trial of family practice clinics in Quebec and Ontario comparing the effect of introducing a Point of Care testing (POCT) for urine albumin to usual practice on quality of care in hypertensive patients with Type 2 diabetes.

Interventions

None listed

Study design

Observational model

CASE_ONLY

Time perspective

PROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Healthy volunteers

Inclusion criteria

* Male or female 18 years and older and able to visit the study sites every 3 months * T2D patients with ongoing anti-diabetic therapy for at least 5 years * Uncontrolled hypertension according to 2012 CHEP recommendations for management of hypertension in diabetic patients ( i.e. BP\> 130/80 mmHg) * Able and agreeing to provide informed consent.

Exclusion criteria

* Type 1 diabetes patients * Ongoing therapy with perindopril, * Known hypersensitivity or allergies to ACEI or sulfonamide derivatives, * A history of angioedema related or not to previous treatment with ACEI, * Impaired renal function defined as serum creatinine levels \> 177 µmol/L, eGFR \<30 mL/min, * Hyperkalemia or hypokalemia, * Severe hepatic impairment, * Use of non-antiarrhythmic agents causing torsade de pointes, * Pregnant or lactating women, or who are planning to become pregnant, * Any conditions which may impact on participation according to treating physician.

Design outcomes

Primary

Measure	Time frame
Stabilisation or improvement of urine albumin excretion status by at least one stage	1 year

Secondary

Measure	Time frame
Microalbuminuria (or further stages of CKD) after 12 months	12 months

Other

Measure	Time frame
Demographics, medical history and medication Diabetes and hypertension status Blood pressure measurements	12 months

Countries

Canada

Contacts

Primary ContactMarie-Renée GUERTIN, project manager

m-r.guertin@medpharmgene.ca514 249 4209

Outcome results